• About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Blog

13 Mar
SEC FIlings

Post-Effective amendments for registration statement

  • March 13, 2023
  • Posted by Ulisses

Read more

13 Mar
SEC FIlings

Post-Effective amendments for registration statement

  • March 13, 2023
  • Posted by Ulisses

Read more

13 Mar
SEC FIlings

Annual Report to Security Holders

  • March 13, 2023
  • Posted by Ulisses

Read more

08 Mar
SEC FIlings

Other definitive proxy statements

  • March 8, 2023
  • Posted by Ulisses

Read more

08 Mar
Press Release

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

  • March 8, 2023
  • Posted by Ulisses
CH Trading Group will serve as exclusive territories distributor in the Middle East and North Africa countries with US $105 million minimum purchase commitment.

Read more

07 Mar
SEC FIlings

Annual report for year ending December 31, 2022

  • March 7, 2023
  • Posted by Ulisses

Read more

03 Mar
SEC FIlings

General statement of acquisition of beneficial ownership

  • March 3, 2023
  • Posted by Ulisses

Read more

01 Mar
SEC FIlings

Current report

  • March 1, 2023
  • Posted by Ulisses

Read more

27 Feb
Press Release

Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

  • February 27, 2023
  • Posted by Ulisses
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The U.S. oral migraine drug market...

Read more

18 Feb
Press Release

Sorrento Posts Form 8937 to Supplement its Previously Issued
“FAQ” Regarding the Dividend of Scilex Holding Company Common
Stock (Nasdaq: SCLX, “Scilex”)

  • February 18, 2023
  • Posted by Ulisses
SAN DIEGO, February 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previouslyissued “Frequently Asked Questions” document under the...

Read more

«‹7891011›»
Close
Recent Posts
  • scilex-no-pic
    Henry Ji, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Stephen Ma
    August 21, 2025 No Comments
  • scilex-no-pic
    Dorman Followwill 
    August 21, 2025 No Comments
  • Alexander Wu, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Jay Chun, MD, PhD
    August 21, 2025 No Comments
scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2025 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

  • <
  • <
  • <
Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info